XOMA Corporation

Type: Public
On the web: http://www.xoma.com
Employees: 188
Employee growth: (18.3%)

XOMA Corporation doesn't want to toil in anonymity. Instead, the company pairs with larger drug firms to develop and market its products, primarily monoclonal antibodies (biotech drugs based on cloned proteins). The firm partners on therapeutics for cancer, infectious disease, inflammatory ailments, and autoimmune conditions; it also receives royalties on drugs developed by companies that have licensed its technologies. XOMA has collaborative agreements with such companies as Takeda Pharmaceutical and Merck; it also works with the National Institutes of Health (NIH) to find treatments for bioterrorism threat botulinum. In addition, XOMA has some proprietary candidates for metabolic and oncology applications.

Key numbers for fiscal year ending December, 2011:
Sales: $58.2M
One year growth: 73.0%
Net income: ($32.7)M

Officers:
Chairman, President, and CEO: Steven B. Engle
VP Operations: Robert S. (Rob) Tenerowicz
VP Finance and CFO: Fred Kurland

Competitors:
MedImmune
Novartis
Regeneron Pharmaceuticals